Marcellus Assiago, MD
Nephrology · Riverton, UTNPI 1235348897
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.2%), food and beverage and education — rather than concentrated in one kind of arrangement. Calliditas Therapeutics US Inc. accounts for 64.0% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $2,688, more than ten times the $195 reported in 2019.
Across 67 payments — averaging $50.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$2K
- Otsuka America Pharmaceutical, Inc.$201
- Amgen$178
- Travere Therapeutics, Inc.$158
- AstraZeneca$157
- Boehringer Ingelheim$102
- plus $420 from 15 others
What the payments were for
- Consulting fees$2,00059%
- Food & beverage$1,22236%
- Education$1575%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 3 | $2,164 |
| Otsuka America Pharmaceutical, Inc. | 7 | $201 |
| Amgen | 10 | $178 |
| Travere Therapeutics, Inc. | 9 | $158 |
| AstraZeneca(2 entities) | 11 | $157 |
| Boehringer Ingelheim | 6 | $102 |
| Bayer | 5 | $81 |
| ANI Pharmaceuticals, Inc. | 2 | $54 |
| Ascendis Pharma Endocrinology Inc | 2 | $35 |
| Alnylam Pharmaceuticals Inc. | 1 | $31 |
| Apellis Pharmaceuticals, Inc. | 1 | $27 |
| Nxstage Medical, Inc. | 1 | $26 |
| Vifor Pharma, Inc. | 1 | $26 |
| Novo Nordisk | 1 | $24 |
| Genentech USA, Inc. | 1 | $20 |
| Medtronic | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Sanofi | 1 | $16 |
| Cormedix Inc. | 1 | $15 |
| Baxter Healthcare | 1 | $15 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$2,145
How this compares
$3,379 in reported general payments places this provider in the 80th percentile of 74 nephrology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 59 | $52,128 |
| FarxigaDapagliflozin Propanediol | 49 | $34,362 |
| Potassium Citrate ErPotassium Citrate | 29 | $1,877 |
| Potassium Chloride | 68 | $1,279 |
| Torsemide | 49 | $1,134 |
| Gentamicin Sulfate | 33 | $1,022 |
| Sevelamer Carbonate | 11 | $940 |
| Calcitriol | 75 | $909 |
| Amlodipine Besylate | 93 | $850 |
| Candesartan Cilexetil | 12 | $838 |
| Telmisartan | 23 | $695 |
| Losartan Potassium | 45 | $375 |
| Chlorthalidone | 21 | $372 |
| Hydralazine Hcl | 14 | $338 |
| Furosemide | 35 | $330 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $102 | $52,12859 claims |
| AstraZenecaFarxiga | $157 | $34,36249 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $54 | $32711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 74 nephrology providers in Utah.
Other nephrology in Riverton
- James ShaffnerRiverton$1K
- Sanjiv AnandSouth Salt Lake$144K
- Alfred CheungSalt Lake City$132K
- Donald KohanSalt Lake City$119K
- Anitha VijayanMurray$118K
- Fuad ShihabSalt Lake City$83K
- William BaragerProvo$13K
- Srinivasa BeddhuSalt Lake City$8K
- George JaradSaint George$7K
- Carlos MercadoSt George$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.